0000000000303186

AUTHOR

J. Barrio

showing 4 related works from this author

Electrochemical Characterization and Dating of Archaeological Leaded Bronze Objects Using the Voltammetry of Immobilized Particles

2017

Financial support from the MINECO Projects CTQ2014-53736-C3-1-P and CTQ2014-53736-C3-2-P, which are supported by ERDF funds, is gratefully acknowledged. We wish to thank the Fondo de Arte y Patrimonio of the Universitat Politecnica de Valencia; the Museu de Prehistoria of Valencia, and its director Helena Bonet and curator Jaime Vives-Ferrandiz; and the Museu Municipal of Xativa and its director Angel Velasco. We also wish to thank Dr Jose Luis Moya Lopez and Mr Manuel Planes Insausti (Microscopy Service of the Universitat Politecnica de Valencia) for technical support.

ArcheologyHistorybiologymedia_common.quotation_subject010401 analytical chemistry02 engineering and technologyArtengineering.material021001 nanoscience & nanotechnologybiology.organism_classification01 natural sciencesArchaeology0104 chemical sciencesengineeringBronze0210 nano-technologyValenciamedia_commonArchaeometry
researchProduct

In vitro tracheal hyperresponsiveness to muscarinic receptor stimulation by carbachol in a rat model of bleomycin-induced pulmonary fibrosis

2006

Summary 1 Bleomycin-induced lung injury is widely used as an experimental model to investigate the pathophysiology of pulmonary fibrosis but the alterations in the pharmacological responsiveness of airways isolated from bleomycin-exposed animals has been scarcely investigated. The aim of this study was to examine the in vitro tracheal responses to muscarinic receptor stimulation with carbachol in a rat bleomycin model. 2 Concentration–response curves to carbachol (10 nm to 0.1 mm) were obtained in tracheal rings isolated from Sprague–Dawley rats 14 days after endotracheal bleomycin or saline. The intracellular calcium signal in response to carbachol (10 μm) was measured by epifluorescence m…

Malemedicine.medical_specialtyCarbacholPulmonary FibrosisStimulationIn Vitro TechniquesMuscarinic AgonistsLung injuryCalcium in biologyProinflammatory cytokineRats Sprague-DawleyBleomycinFibrosisInternal medicinePulmonary fibrosisMuscarinic acetylcholine receptormedicineAnimalsCalcium SignalingPharmacologyDose-Response Relationship DrugTumor Necrosis Factor-alphabusiness.industryMuscle Smoothrespiratory systemmedicine.diseaseReceptors MuscarinicRatsTracheaDisease Models AnimalEndocrinologyCarbacholBronchial HyperreactivitybusinessInterleukin-1Muscle Contractionmedicine.drugAutonomic and Autacoid Pharmacology
researchProduct

Measurement of inclusive K*(0)(892), phi(1020) and K-2*(0)(1430) production in hadronic Z decays

1996

The inclusive production of the neutral vector mesons K-*0(892) and phi(1020), and of the tensor meson K-2(*0)(1430), in hadronic decays of the Z has been mea sured by the DELPHI detector at LEP. The average production rates per hadronic Z decay have been determined to be 0.77 +/- 0.08 K-2(*0)(892), 0.104 +/- 0.008 phi(1020) and 0.079 +/- 0.040 K-2(*0)(1430). The ratio of the tensor-to-vector meson production yields, [K-2(*0)(1430)]/[K-*0(892)] = 0.10 +/- 0.05, is smaller than the [f(2)(1270)]/[rho(0)(770)] and [f'(2)(1525)]/[phi(1020)] ratios measured by DELPHI. The production rates and differential cross sections are compared with the predictions of JETSET 7.4 tuned to the DELPHI data and…

Particle physicsMeson productionPhysics and Astronomy (miscellaneous)MesonElectron–positron annihilationHadronVECTORproduction rate01 natural sciencesPartícules (Física nuclear)DELPHI; neutral vector meson; tensor meson; production rateNuclear physics0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]MESON; VECTOR; GEV/Cneutral vector mesonTensorNeutral vector010306 general physicsDetectors de radiacióDELPHIPhysics010308 nuclear & particles physicstensor mesonGEV/CMass spectrumProduction (computer science)MESON
researchProduct

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management…

2020

Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infect…

medicine.medical_specialtyAllergySettore MED/12 - GASTROENTEROLOGIAallergicPenicillinsGastroenterologyHelicobacter InfectionsDrug Hypersensitivity03 medical and health sciences0302 clinical medicineLevofloxacinMetronidazoleClarithromycinInternal medicinebismuthmedicineHumansProspective StudiesRegistriesAdverse effectlevofloxacinbiologyHelicobacter pyloribusiness.industrySettore MED/09 - MEDICINA INTERNAallergic ; allergy ; bismuth ; clarithromycin ; Helicobacter pylori ; levofloxacin ; penicillinGastroenterologyProton Pump InhibitorsGeneral MedicineTetracyclineHelicobacter pyloribiology.organism_classificationmedicine.diseaseallergyclarithromycinAnti-Bacterial Agents3. Good healthPenicillinMetronidazoleRegimenInfectious Diseasespenicillin030220 oncology & carcinogenesisDrug Therapy Combination030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct